Proposed Changes to BenevolentAI’s Board Composition - Seite 2

“It has been a privilege to lead this excellent board and I would like to take this opportunity to extend our appreciation to Olivier, Susan and Marcello for their significant contributions to the Board since joining. The Company has benefitted significantly from their wise counsel and experience.”

Biographies of the Non-Executive Directors to be proposed at the AGM:

Mr. Peter Allen

A chartered accountant by background, Peter has over 30 years’ experience as an Executive Director, Non-Executive Director and Chairman in a wide range of life science companies, playing a significant role in their growth. He spent nine years as Chairman of Clinigen plc from 2012 up to its 2021 US$1.8 billion sale to Triton; three years as Chairman of Proximagen Group plc from 2009 to its 2012 headline sale of US$553 million to Upsher-Smith; six years at ProStrakan Group plc as its Chairman from 2007 up to 2013 guiding it through its £292 million acquisition by Japan’s KHK; and 12 years at Celltech Group plc from 1992 to 2004 as CFO and latterly Deputy CEO.

Peter is currently a Non-Executive Director at Istesso Ltd. and recently retired as Non-Executive Chairman at Abcam plc after its US$5.7 billion sale to Danaher. He is also a former Non-Executive Chairman of Oxford Nanopore, where he served for 11 years from 2011 to 2022 and AIM listed Advanced Medical Solutions plc where he brought his substantial experience in M&A, international growth, fundraising and investor relations, as well as the commercialisation of intellectual property.

Mr. Kenneth Mulvany

Kenneth is a prominent figure in the intersection of technology and bioscience and is known for his entrepreneurial spirit and innovative contributions to drug discovery. He is the founder of BenevolentAI and was the Company’s Chairman from its 2013 foundation until July 2021 when it stood at the forefront of applying AI to scientific discovery, particularly in the biopharmaceutical domain.

Under Kenneth’s leadership BenevolentAI transitioned from a small group to a market leader by achieving early commercial success. This trajectory led to the honour of being named a 2018 Technology Pioneer by the World Economic Forum, alongside past honourees including Google, Twitter and Palantir, acknowledging their transformative impacts in technology and society.

Before establishing BenevolentAI, he was the founder and CEO of Proximagen Group plc, (“Proximagen”) a leading biotech firm specialising in the development of medicines to treat neurodegeneration. Proximagen was sold to Upsher-Smith for a headline value of US$553 million. This experience, coupled with his observation of the exponential increase in scientific information and the challenges in utilising this vast and complex data, inspired him to venture into AI with the creation of BenevolentAI in November 2013.